Opus Financial Statements From 2010 to 2025

IRD Stock   1.96  0.03  1.51%   
Opus Genetics,'s financial statements offer valuable quarterly and annual insights to potential investors, highlighting the company's current and historical financial position, overall management performance, and changes in financial standing over time. Key fundamentals influencing Opus Genetics,'s valuation are provided below:
Gross Profit
-12.8 M
Market Capitalization
139.3 M
Enterprise Value Revenue
7.4872
Revenue
14.6 M
Earnings Share
(1.86)
There are over one hundred nineteen available trending fundamental ratios for Opus Genetics,, which can be analyzed over time and compared to other ratios. Investors should ensure to check out all of Opus Genetics,'s recent performance against the performance from 2010 to 2025 to make sure the company is sustainable down the road. The current year's Enterprise Value is expected to grow to about 21.3 M, whereas Market Cap is forecasted to decline to about 16 M.

Opus Genetics, Total Revenue

15.51 Million

Check Opus Genetics, financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Opus Genetics,'s main balance sheet or income statement drivers, such as Depreciation And Amortization of 6.4 K, Interest Expense of 0.0 or Selling General Administrative of 9.2 M, as well as many indicators such as Price To Sales Ratio of 2.75, Dividend Yield of 0.0 or PTB Ratio of 4.96. Opus financial statements analysis is a perfect complement when working with Opus Genetics, Valuation or Volatility modules.
  
Build AI portfolio with Opus Stock
Check out the analysis of Opus Genetics, Correlation against competitors.
For information on how to trade Opus Stock refer to our How to Trade Opus Stock guide.

Opus Genetics, Balance Sheet

Current ValueLast YearHistorical Average 10 Year Trend
Total Assets34 M36.9 M14.7 M
Slightly volatile
Short and Long Term Debt Total22.8 M21.7 M8.7 M
Slightly volatile
Other Current Liabilities8.6 M8.1 M3.6 M
Slightly volatile
Total Current Liabilities6.3 M11.3 M7.8 M
Slightly volatile
Accounts Payable1.7 M3.1 M895.7 K
Slightly volatile
Cash30.4 M30.3 M13.1 M
Slightly volatile
Cash And Short Term Investments30.5 M30.3 M13.2 M
Slightly volatile
Common Stock Shares Outstanding17.5 M26.7 M11.1 M
Slightly volatile
Liabilities And Stockholders Equity34 M36.9 M14.7 M
Slightly volatile
Other Current Assets489.2 K515 K446.2 K
Slightly volatile
Other Stockholder Equity96.5 M145.7 M39.2 M
Slightly volatile
Total Liabilities31.6 M30.1 M12.3 M
Slightly volatile
Total Current Assets33.9 M36.6 M14.7 M
Slightly volatile
Short Term Debt460 K484.2 K3.7 M
Slightly volatile
Property Plant And Equipment Gross20 K22.5 K24.5 K
Slightly volatile
Capital Stock2.2 KK1.4 K
Slightly volatile
Net Working Capital34.8 M25.3 M21.1 M
Slightly volatile
Common Stock2.2 KK1.4 K
Slightly volatile
Short and Long Term Debt430.4 K484.2 K527.9 K
Slightly volatile

Opus Genetics, Income Statement

Current ValueLast YearHistorical Average 10 Year Trend
Depreciation And Amortization6.4 K10 K4.3 K
Slightly volatile
Selling General Administrative9.2 M18.2 M4.7 M
Slightly volatile
Other Operating Expenses76.7 M73.1 M17.9 M
Slightly volatile
Research Development15.2 M26.9 M7.5 M
Slightly volatile
Total Operating Expenses76.7 M73.1 M17.9 M
Slightly volatile
Cost Of RevenueK10 K7.4 K
Slightly volatile
Reconciled DepreciationK10 K7.4 K
Slightly volatile
Income Tax Expense10.3 K10.8 K258 K
Slightly volatile

Opus Genetics, Cash Flow Statement

Current ValueLast YearHistorical Average 10 Year Trend
Stock Based Compensation2.3 M3.4 M1.1 M
Slightly volatile
Begin Period Cash Flow53 M50.5 M12.1 M
Slightly volatile
Depreciation6.4 K10 K4.3 K
Slightly volatile
Other Non Cash Items14.5 M25.5 M6.9 M
Slightly volatile
Total Cash From Financing ActivitiesM4.2 M7.3 M
Pretty Stable
End Period Cash Flow30.4 M30.3 M13.1 M
Slightly volatile
Issuance Of Capital Stock4.3 M4.5 M17.7 M
Slightly volatile

Financial Ratios

Current ValueLast YearHistorical Average 10 Year Trend
Price To Sales Ratio2.752.892224.8817
Slightly volatile
Days Sales Outstanding20119263.4447
Slightly volatile
Stock Based Compensation To Revenue0.290.30592.4888
Slightly volatile
Capex To Depreciation6.667.58.1767
Slightly volatile
Payables Turnover0.00410.00320.0056
Slightly volatile
Sales General And Administrative To Revenue1.571.657110.5932
Slightly volatile
Research And Ddevelopement To Revenue2.322.442819.6986
Slightly volatile
Cash Per Share1.471.1350.9024
Slightly volatile
Days Payables Outstanding75.7 K117.9 K70.6 K
Slightly volatile
Income Quality0.470.44460.5168
Slightly volatile
Current Ratio6.253.24133.4267
Slightly volatile
Receivables Turnover1.811.90447.4184
Slightly volatile
Capex Per Share0.00280.00320.0035
Slightly volatile
Revenue Per Share0.390.41140.2599
Slightly volatile
Interest Debt Per Share0.610.70530.8038
Slightly volatile
Debt To Assets0.560.592.1237
Slightly volatile
Graham Number5.476.166.7159
Slightly volatile
Operating Cycle20119263.4447
Slightly volatile
Days Of Payables Outstanding75.7 K117.9 K70.6 K
Slightly volatile
Ebt Per Ebit1.490.92681.4251
Pretty Stable
Quick Ratio6.253.24133.4267
Slightly volatile
Net Income Per E B T0.790.90.9666
Slightly volatile
Cash Ratio2.552.68452.8983
Slightly volatile
Days Of Sales Outstanding20119263.4447
Slightly volatile
Free Cash Flow Operating Cash Flow Ratio0.810.910.9886
Slightly volatile
Fixed Asset Turnover47.6550.16468
Pretty Stable
Debt Ratio0.560.592.1237
Slightly volatile
Price Sales Ratio2.752.892224.8817
Slightly volatile
Asset Turnover0.30.29820.1272
Slightly volatile
Gross Profit Margin0.80.90.9805
Slightly volatile

Opus Genetics, Valuation Data

Current ValueLast YearHistorical Average 10 Year Trend
Market Cap16 M31.8 M13.6 M
Slightly volatile

Opus Fundamental Market Drivers

About Opus Genetics, Financial Statements

Opus Genetics, stakeholders use historical fundamental indicators, such as Opus Genetics,'s revenue or net income, to determine how well the company is positioned to perform in the future. Although Opus Genetics, investors may analyze each financial statement separately, they are all interrelated. For example, changes in Opus Genetics,'s assets and liabilities are reflected in the revenues and expenses on Opus Genetics,'s income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in Opus Genetics,. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Total Revenue11 M15.5 M
Cost Of Revenue10 KK
Stock Based Compensation To Revenue 0.31  0.29 
Sales General And Administrative To Revenue 1.66  1.57 
Research And Ddevelopement To Revenue 2.44  2.32 
Revenue Per Share 0.41  0.39 
Ebit Per Revenue(5.65)(5.93)

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.
When determining whether Opus Genetics, is a strong investment it is important to analyze Opus Genetics,'s competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Opus Genetics,'s future performance. For an informed investment choice regarding Opus Stock, refer to the following important reports:
Check out the analysis of Opus Genetics, Correlation against competitors.
For information on how to trade Opus Stock refer to our How to Trade Opus Stock guide.
You can also try the Options Analysis module to analyze and evaluate options and option chains as a potential hedge for your portfolios.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Opus Genetics,. If investors know Opus will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Opus Genetics, listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(1.86)
Revenue Per Share
0.295
Quarterly Revenue Growth
(0.20)
Return On Assets
(0.61)
Return On Equity
(3.39)
The market value of Opus Genetics, is measured differently than its book value, which is the value of Opus that is recorded on the company's balance sheet. Investors also form their own opinion of Opus Genetics,'s value that differs from its market value or its book value, called intrinsic value, which is Opus Genetics,'s true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Opus Genetics,'s market value can be influenced by many factors that don't directly affect Opus Genetics,'s underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Opus Genetics,'s value and its price as these two are different measures arrived at by different means. Investors typically determine if Opus Genetics, is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Opus Genetics,'s price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.